We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
+34.12%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$73.8M
AUM Growth
+$28.4M
(+62%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
23.17%
Top 10 Holdings %
Top 10 Hldgs %
55.69%
Holding
77
New
37
Increased
5
Reduced
25
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.64M |
| 2 |
Direxion Daily S&P Biotech Bull 3X ETF
LABU
|
+$1.49M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$1.01M |
| 4 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$713K |
| 5 |
Insmed
INSM
|
+$698K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LOXO
Loxo Oncology, Inc
LOXO
|
+$870K |
| 2 |
Biogen
BIIB
|
+$320K |
| 3 |
Exelixis
EXEL
|
+$233K |
| 4 |
Ionis Pharmaceuticals
IONS
|
+$141K |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$130K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 57.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
iShares Biotechnology ETF
IBB
$9.23B
| $14M | 18.94% |
125,000
| – | – |
|
|
2
CALL
iShares Biotechnology ETF
IBB
$9.23B
| $9.5M | 12.88% |
85,000
| – | – |
|
|
3
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
| $5.87M | 7.95% |
4,901
+1,436
| +41% | +$1.49M |
|
4
Mettler-Toledo International
MTD
$26.5B
| $2.34M | 3.17% |
3,235
| – | – |
|
5
ProQR Therapeutics
PRQR
$240M
| $1.92M | 2.6% |
138,461
| – | – |
|
|
6
Ionis Pharmaceuticals
IONS
$8.99B
| $1.63M | 2.21% |
20,124
-2,183
| -10% | -$141K |
|
|
7
Bristol-Myers Squibb
BMY
$124B
| $1.57M | 2.13% |
+33,000
| New | +$1.64M |
|
8
Vertex Pharmaceuticals
VRTX
$123B
| $1.49M | 2.01% |
8,074
-590
| -7% | -$109K |
|
9
Illumina
ILMN
$28.2B
| $1.45M | 1.97% |
4,806
-239
| -5% | -$69.7K |
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.34M | 1.82% |
9,927
-560
| -5% | -$69.6K |
|
|
SGEN
11
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.31M | 1.77% |
17,832
-1,295
| -7% | -$92.1K |
|
12
Alnylam Pharmaceuticals
ALNY
$35.7B
| $1.25M | 1.69% |
13,351
-904
| -6% | -$75.6K |
|
|
IMMU
13
DELISTED
Immunomedics Inc
IMMU
| $1.2M | 1.63% |
+62,575
| New | +$1.01M |
|
14
Qiagen
QGEN
$8.49B
| $1.17M | 1.59% |
27,215
-2,456
| -8% | -$98.8K |
|
|
ONCE
15
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $1.1M | 1.5% |
+9,699
| New | +$713K |
|
|
BLUE
16
DELISTED
bluebird bio
BLUE
| $919K | 1.25% |
451
+240
| +114% | +$423K |
|
17
Incyte
INCY
$23.4B
| $913K | 1.24% |
10,613
-1,592
| -13% | -$130K |
|
|
18
Regeneron Pharmaceuticals
REGN
$70.9B
| $904K | 1.23% |
2,201
-315
| -13% | -$130K |
|
19
uniQure
QURE
$2.77B
| $848K | 1.15% |
+14,215
| New | +$635K |
|
20
BioMarin Pharmaceuticals
BMRN
$11.5B
| $808K | 1.1% |
9,099
-599
| -6% | -$55.5K |
|
|
CELG
21
DELISTED
Celgene Corp
CELG
| $803K | 1.09% |
8,510
-1,473
| -15% | -$129K |
|
|
22
Insmed
INSM
$23.5B
| $783K | 1.06% |
+26,936
| New | +$698K |
|
23
Ascendis Pharma A/S
ASND
$17.1B
| $729K | 0.99% |
+6,190
| New | +$542K |
|
|
BOLD
24
DELISTED
Audentes Therapeutics, Inc
BOLD
| $677K | 0.92% |
+17,339
| New | +$497K |
|
|
ICPT
25
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $644K | 0.87% |
5,756
+2,222
| +63% | +$243K |
|
Similar funds
KIA
PGA
GX
SCG
TCMV
DP
SAM
ACP
Opus Point Partners Management's Q1 2019 Portfolio in Review
As of Q1 2019, Opus Point Partners Management held 77 positions worth $73.8M, up 62% from $45.4M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Opus Point Partners Management deployed $17.1M of net new capital in Q1 2019, opening 37 new positions and adding to 5 existing holdings. Its largest new stake was Bristol-Myers Squibb: 33,000 shares worth $1.57M.
By sector, the portfolio is most concentrated in Healthcare at 57% of assets, up from 50% a quarter earlier.
On the sell side, the largest reduction was Exelixis, an estimated $233K trimmed.
- Opus Point Partners Management's largest Q1 2019 buy was Bristol-Myers Squibb: 33,000 shares worth $1.57M.
- Opus Point Partners Management added most to Direxion Daily S&P Biotech Bull 3X ETF in Q1 2019, an estimated $1.49M increase.
- Opus Point Partners Management's biggest Q1 2019 reduction was Exelixis, cutting an estimated $233K.
- Opus Point Partners Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $870K.
- Opus Point Partners Management's ten largest holdings make up 56% of its $73.8M portfolio in Q1 2019.
- Opus Point Partners Management opened 37 new positions and closed 2 in Q1 2019.
- Opus Point Partners Management's portfolio value rose 62% quarter-over-quarter to $73.8M.
Based on Opus Point Partners Management's 13F filing for Q1 2019, filed 15 May 2019.